The antioxidative-prooxidative balance in children with asthma treated with inhaled corticosteroids and long acting β2-agonists;Równowaga antyoksydacyjno-prooksydacyjna u dzieci z astma̧ leczonych kortykosteroidami wziewnymi i długo działaja̧cymi β2-mimetykami

Pneumonologia i Alergologia Polska

Volumn 73, Issue 2, 2005, Pages 178-181

  Szlagatys Sidorkiewicz, Agnieszka ^a,c   Korzon, Maria ^a   Małaczyńska, Teresa ^b   Renke, Joanna ^a   Popadiuk, Stefan ^a   Woźniak, Michał ^b  

^a Klinika Pediatrii   (Poland)

^b Szpital Dzieciȩcego ^*  (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antioxidative barrier; Asthma; Oxidative stress; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBONYL DERIVATIVE; CORTICOSTEROID; PLASMA PROTEIN; SUPEROXIDE DISMUTASE;

ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; OXIDATIVE STRESS;

EID: 33244457811     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Antczak A. i wsp.: Inhaled glucocorticosteroids decrease hydrogen peroxide level in expired air condensate in asthmatic patients. Respir. Med. 2000, 94, 416-21.
2. Baraldi E. i wsp.: Increased exhaled 8-isoprostane in childhood asthma. Chest 2003, 124, 25-31.
3. Ceylan E. i wsp. Evaluation of oxidative-antioxidative status and the 1-arginine-nitric oxide pathway in asthmatic patients. Respir. Med. 2005, 99, 871-6.
4. Chevion M. Bereshtein E., Stadtman E.: Human studies related to protein oxidation: Protein carbonyl content as a marker of damage. Free Rad. Res. 2000, 33, 99-108.
5. DeRaeve H.R. i wsp.: Decreased Cu,Zn-SOD activity in asthmatic airway epithelium correction by inhaled corticosteroid in vivo. Am. J. Physiol. 1997, 272, L148-154.
6. Dorski R. i wsp.: Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am. J. Respir. Crit. Care Med. 1999, 160, 1947-51.
7. Ezeamuzie C.I., Al-Hage M.: Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation. Int. Arch. Allergy Immunol. 1998, 115, 162-168.
8. Hanta I. i wsp.: The oxidant-antioxidant balance in mild asthmatic patients. Lung 2003, 181, 347-52.
9. Horvath I. i wsp.: Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am. J. Respir. Crit Care Med. 1998, 158, 1042-6.
10. Levine R.L. i wsp.: Determination of carbonyl content in oxidatively modified proteins. Meth. Enzymol. 1990, 186, 464-478.
11. Liao M.F., Chen C.C., Hsu M.H.: Evaluation of the serum antioxidant status in asthmatic children. Acta Paediatr. Taiwan. 2004, 45, 213-7.
12. Mac Pherson J.C. i wsp.: Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J. Immunol. 2001, 166, 5763-72.
13. Majori M. i wsp.: Superoxide anion production by monocytes of corticosteroid-treated asthmatic patients. Eur. Respir. J. 1998, 11, 133-138.
14. Minami M, Yoshikawa H 1979 A simplified assay method of superoxide dismutase activity for clinical use. Clin Chim Acta 92:337-42
15. Nadeem A. i wsp.: Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol. 2003, 111, 72-8.
16. National Heart, Lung, Blood Institute, National Institute of Health: Global Strategy for Asthma Management and Prevention 1995, 95-3659, 6.
17. Niwa Y., Ishimoto K., Kanoh T.: Induction of superoxide dismutase in leukocytes by paraquat: correlation with age and possible predictor of longevity. Blood 1990, 76, 835-41.
18. Ozaras R. i wsp. Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist. Respirology 2000, 5, 289-92.
19. Rahman I., Clerch R.C., Massaro D.: Rat lung antioxidant enzyme induction by ozone. Am. J. Physiol. 1991, 260 (6Pt1), L412-8.
20. Renke J. i wsp.: Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic. Biol. Med. 2000, 29, 101-4.
21. Sannohe S. i wsp.: Upregulated response to chemokines in oxidative metabolism of eosinophils in asthma and allergic rhinitis. Eur. Respir. J. 2003, 21, 925-31.
22. Schock B.C. i wsp.: Antioxidants and oxidative stress in BAL fluid of atopic asthmatic children. Pediatr. Res. 2003, 53, 375-81.
23. Shanmugasundaram K.R., Kumar S.S., Rajajee S.: Excessive free radical generation in the blood of children suffering from asthma Clin. Chim. Acta 2001, 305, 107-114.
24. Sies H.: Oxidative stress: From basic research to clinical application. Am. J. Med. 1991, 91 (suppl 3C), 3C-31S -3C-38S.
25. Tanswell A.K., Tzaki M.G., Byrne P.J.: Hormonal and local factors influence antioxidant enzyme activity of rat fetal lung cells in vitro. Exp. Lung Res. 1986, 11, 49-59.
26. Tekin D. i wsp.: The antioxidant defense in asthma. J Asthma, 2000, 37, 59-63.
27. Tsukagoshi H. i wsp. Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir. Med. 2000, 94, 584-8.
28. Wood L.G. i wsp.: Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 2000, 35, 967-974.
29. Yazici C. i wsp.: Increased advanced oxidation protein products in Behcet's disease: a new activity marker? Br. J. Dermatol. 2004, 151, 105-11.
30. Zanconato S. i wsp.: Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J. Allergy Clin. Immunol. 2004, 113, 257-63.